ProCE Banner Activity

Expanding the Applicability Beyond HER2m and EGFRm: TROP-2–Targeted ADCs in NSCLC and ADCs in Patients with SCLC

Slideset

Downloadable slides from a live satellite symposium on the use of TROP-2–targeted ADCs for patients with NSCLC and new data on the future of ADCs in patients with SCLC.

Released: September 16, 2024

Expiration: September 15, 2025

Share

Faculty

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.